13F Filings History of Abingworth LLP

Latest 13F report
Q4 2025 - 13 Feb 2026
Signature - Title
John Heard - General Counsel
Location
London
Summary
This page shows a list of all the recent 13F filings made by Abingworth LLP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Abingworth LLP reported 19 stock holdings with total value $303,519,560 as of Q4 2022. Top holdings included PCVX, VRNA, VERA, HLVX, and ACET. Carlyle Group Inc. is reporting for Abingworth LLP.

Notify me when Abingworth LLP files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value

Carlyle Group Inc. is reporting for Abingworth LLP:

Name Holdings Value Location File Number
Carlyle Group Inc. $13,566,904,392 Washington, DC 028-15025
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2025 $0 13F-NT 13 Feb 2026, 16:35
Q3 2025 $0 13F-NT 07 Nov 2025, 16:42
Q2 2025 $0 13F-NT 08 Aug 2025, 17:18
Q1 2025 $0 13F-NT 09 May 2025, 16:48
Q4 2024 $0 13F-NT 13 Feb 2025, 17:03
Q3 2024 $0 13F-NT 08 Nov 2024, 17:00
Q2 2024 $0 13F-NT 09 Aug 2024, 16:47
Q1 2024 $0 13F-NT 03 May 2024, 16:39
Q4 2023 0 $0 13F-NT 02 Feb 2024, 16:47
Q3 2023 0 $0 13F-NT 03 Nov 2023, 16:44
Q2 2023 0 $0 13F-NT 04 Aug 2023, 16:41
Q1 2023 0 $0 13F-NT 05 May 2023, 17:01
Q4 2022 19 $303,519,560 $0 -$103,076,245 -$103,076,245 PCVX, VRNA, VERA, HLVX, ACET 13F-HR 10 Feb 2023, 16:28
Q3 2022 19 $292,325,000 +$4,920,000 -$79,153,000 -$74,233,000 PCVX, VERA, HLVX, ACET, VRNA 13F-HR 10 Nov 2022, 16:48
Q2 2022 21 $312,400,000 +$19,935,329 -$14,682,474 +$5,252,855 PCVX, SRRA, VERA, ACET, HLVX 13F-HR 15 Aug 2022, 06:30
Q1 2022 20 $352,495,000 +$18,868,115 $0 +$18,868,115 PCVX, VERA, ACET, SRRA, JSPR 13F-HR 16 May 2022, 07:00
Q4 2021 20 $412,700,000 +$8,719,926 $0 +$8,719,926 PCVX, VERA, JSPR, EFTR, ACET 13F-HR 16 Feb 2022, 11:26
Q3 2021 20 $440,666,000 +$126,001,693 -$1,729,030 +$124,272,663 PCVX, EFTR, JSPR, VERA, PHAT 13F-HR 15 Nov 2021, 06:05
Q2 2021 19 $323,501,000 +$56,703,000 $0 +$56,703,000 PCVX, PHAT, VERA, Spruce Bio, SIEN 13F-HR 16 Aug 2021, 06:30
Q1 2021 17 $289,551,000 +$22,924,000 $0 +$22,924,000 PCVX, PHAT, Spruce Bio, ACET, VRNA 13F-HR 17 May 2021, 06:11
Q4 2020 15 $292,327,000 +$43,074,000 -$118,815,438 -$75,741,438 PCVX, Spruce Bio, PHAT, SLNO, VRNA 13F-HR 01 Mar 2021, 11:18
Q3 2020 17 $467,504,000 +$27,283,800 -$43,068,792 -$15,784,992 PCVX, PSNL, PHAT, SLNO, CRSP 13F-HR 16 Nov 2020, 06:15
Q2 2020 16 $354,662,000 +$138,889,740 -$3,966,000 +$134,923,740 PCVX, PSNL, PHAT, CRSP, SLNO 13F-HR 14 Aug 2020, 15:27
Q1 2020 16 $150,582,000 +$9,086,689 -$879,000 +$8,207,689 PSNL, PHAT, CRSP, SLNO, XCUR 13F-HR 14 May 2020, 06:05
Q4 2019 16 $206,909,000 +$48,927,774 -$6,650,247 +$42,277,527 PSNL, PHAT, CRSP, SIEN, SLNO 13F-HR 14 Feb 2020, 06:05
Q3 2019 14 $158,151,000 +$15,750,000 -$38,037,027 -$22,287,027 PSNL, CRSP, XCUR, SIEN, SLNO 13F-HR 14 Nov 2019, 06:06
Q2 2019 14 $260,762,000 +$147,948,000 -$13,817,582 +$134,130,418 PSNL, CRSP, SIEN, AVDR, SLNO 13F-HR 14 Aug 2019, 06:09
Q1 2019 14 $111,733,000 +$13,401,104 -$12,545,286 +$855,818 CRSP, SIEN, CHMA, SLNO, AVDR 13F-HR 15 May 2019, 06:15
Q4 2018 16 $110,057,000 +$7,984,000 -$4,318,904 +$3,665,096 CRSP, SIEN, VRNA, SLNO, CHMA 13F-HR 14 Feb 2019, 06:16
Q3 2018 16 $168,201,000 +$11,274,000 -$11,917,738 -$643,738 CRSP, SIEN, VRNA, PRTK, OBSVF 13F-HR 14 Nov 2018, 06:15
Q2 2018 16 $175,043,000 +$7,216,578 -$38,753,006 -$31,536,428 CRSP, SIEN, PRTK, OBSVF, GTXI 13F-HR 14 Aug 2018, 07:00
Q1 2018 16 $160,870,000 +$2,976,000 -$18,102,523 -$15,126,523 CRSP, SIEN, PRTK, GTXI, OBSVF 13F-HR 15 May 2018, 06:08
Q4 2017 17 $138,016,000 $0 -$4,444,154 -$4,444,154 CRSP, SIEN, PRTK, CBAY, OBSVF 13F-HR 14 Feb 2018, 06:10
Q3 2017 18 $144,439,000 +$8,612,000 -$16,831,471 -$8,219,471 CRSP, SIEN, PRTK, CBAY, CHMA 13F-HR 14 Nov 2017, 06:13
Q2 2017 16 $125,658,000 $0 -$3,446,236 -$3,446,236 CRSP, PRTK, SIEN, CBAY, CASC 13F-HR 14 Aug 2017, 06:02
Q1 2017 17 $134,219,000 +$6,724,239 -$2,182,953 +$4,541,286 CRSP, PRTK, SIEN, CBAY, CASC 13F-HR 15 May 2017, 07:36
Q4 2016 18 $118,741,000 +$53,189,416 -$13,748,245 +$39,441,171 CRSP, PRTK, SIEN, NOVN, CHMA 13F-HR 14 Feb 2017, 06:04
Q3 2016 20 $104,334,000 +$4,796,387 -$7,613,441 -$2,817,054 SIEN, PRTO, PRTK, CEMP, CHMA 13F-HR 14 Nov 2016, 07:20
Q2 2016 20 $95,498,000 +$4,784,622 -$533,000 +$4,251,622 PRTK, PRTO, SIEN, TBRA, CEMP 13F-HR 12 Aug 2016, 06:03
Q1 2016 19 $107,619,000 +$256,000 $0 +$256,000 PRTK, CHMA, PRTO, SIEN, CEMP 13F-HR 13 May 2016, 06:16
Q4 2015 18 $165,700,000 +$6,113,000 -$368,993 +$5,744,007 CHMA, PRTO, PRTK, SIEN, CEMP 13F-HR 16 Feb 2016, 07:22
Q3 2015 17 $171,209,000 +$46,093,000 -$21,111,360 +$24,981,640 CHMA, PRTO, PRTK, SIEN, EVAR 13F-HR 13 Nov 2015, 06:49
Q2 2015 16 $216,417,000 +$18,975,399 -$47,531,244 -$28,555,845 SIEN, PRTO, PRTK, AMRN, EVAR 13F-HR 14 Aug 2015, 06:47
Q1 2015 17 $235,176,000 +$1,024,000 -$157,158,138 -$156,134,138 SIEN, PRTK, SUPN, DRNA, PRTO 13F-HR 14 May 2015, 06:03
Q4 2014 16 $352,088,000 +$108,002,751 -$56,000 +$107,946,751 RNA, PRTK, SIEN, PTLA, SUPN 13F-HR 13 Feb 2015, 06:12
Q3 2014 13 $167,253,000 +$25,703,000 -$14,201,284 +$11,501,716 RNA, EVAR, SUPN, PTLA, DRNA Restatement 25 Nov 2014, 15:07
Q2 2014 12 $215,201,000 +$1,581,000 -$7,630,000 -$6,049,000 RNA, SUPN, PTLA, DRNA, AMRN 13F-HR 14 Aug 2014, 06:53
Q1 2014 13 $181,248,000 +$36,257,000 $0 +$36,257,000 RNA, DRNA, SUPN, PTLA, AMRN 13F-HR 20 May 2014, 18:33
Q4 2013 11 $132,698,000 $0 $0 $0 PTLA, RNA, SUPN, AMRN, CEMP 13F-HR 14 Feb 2014, 08:47